Long-Term Nephrotoxicity of 177 Lu-PSMA Radioligand Therapy
Journal of Nuclear Medicine · 2024-01 · 65 (1) · 79-84
DOI: 10.2967/jnumed.123.265986 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 19.10.2023. Verfasst von Lisa Steinhelfer und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, and Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
β-emitting 177Lu targeting prostate-specific membrane antigen (PSMA) is an approved treatment option for metastatic castration-resistant prostate cancer. Data on its long-term nephrotoxicity are sparse. This study aimed to retrospectively evaluate post-177Lu-PSMA estimated glomerular filtration rate (eGFR) dynamics for at least 12 mo in a cohort of metastatic castration-resistant prostate cancer patients. Methods: The institutional databases of 3 German tertiary referral centers identified 106 patients who underwent at least 4 cycles of 177Lu-PSMA and had at least 12 mo of eGFR follow-up data. eGFR (by the Chronic Kidney Disease Epidemiology Collaboration formula) at 3, 6, and 12 mo after 177Lu-PSMA radioligand therapy was estimated using monoexponentially fitted curves through available eGFR data. eGFR changes were grouped (≥15%-
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, School of Medicine, and Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
- Department of Radiology, School of Medicine, and Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
- Department of Urology, School of Medicine, and Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; lukas.lunger@tum.de.
- Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Department of Nuclear Medicine, University Hospital Wurzburg, Wurzburg, Germany.
- Department of Nephrology, School of Medicine, and Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; and.
Zitieren
APA
Steinhelfer, L., Lunger, L., Cala, L., Pfob, C. H., Lapa, C., Hartrampf, P. E., Buck, A. K., Schäfer, H., Schmaderer, C., Tauber, R., Brosch-Lenz, J., Haller, B., Meissner, V. H., Knorr, K., Weber, W. A., & Eiber, M. (2024). Long-Term Nephrotoxicity of 177 Lu-PSMA Radioligand Therapy. Journal of Nuclear Medicine, 65(1), 79-84. https://doi.org/10.2967/jnumed.123.265986
Vancouver
Steinhelfer L, Lunger L, Cala L, Pfob CH, Lapa C, Hartrampf PE, et al. Long-Term Nephrotoxicity of 177 Lu-PSMA Radioligand Therapy. Journal of Nuclear Medicine. 2024;65(1):79-84. doi:10.2967/jnumed.123.265986
BibTeX
@article{Steinhelfer2024,
author = {Steinhelfer, Lisa and Lunger, Lukas and Cala, Lisena and Pfob, Christian H and Lapa, Constantin and Hartrampf, Philipp E and Buck, Andreas K and Schäfer, Hannah and Schmaderer, Christoph and Tauber, Robert and Brosch-Lenz, Julia and Haller, Bernhard and Meissner, Valentin H and Knorr, Karina and Weber, Wolfgang A and Eiber, Matthias},
title = {Long-Term Nephrotoxicity of 177 Lu-PSMA Radioligand Therapy},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {1},
pages = {79--84},
doi = {10.2967/jnumed.123.265986}
}
EUVIMED